Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib - Top-Institutions - MDSpire

Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib

  • By

  • Lisa Heß

  • Jule Koch

  • Finja Göttsche

  • Thomas Reinheckel

  • June 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Translational Breast Cancer Research Consortium
    Translational Breast Cancer Research Consortium

    N/A, N/A

    Key Differentiators

    • Oncology

  • #3

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

  • #4

    Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical Center

    Boston, MA

    Key Differentiators

    • Oncology

  • #5

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

Original Source(s)

Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib

  • by Lisa Heß, Jule Koch, Finja Göttsche, Thomas Reinheckel

  • June 10, 2026

Related Content

Development and validation of an interpretable machine learning model for predicting 5-year recurrence in breast cancer

Multidisciplinary team care and outcomes in FNCLCC grade 3 soft tissue sarcoma: a propensity score–matched and weighted cohort study

Combination of metformin and parthenolide inhibits breast cancer in mice by apoptosis induction and angiogenesis inhibition